This report was first published by Endpoints News. To see the original version, click here
Indian drug giant Sun Pharma has lined up an $11.75 billion acquisition of Organon, a women’s health and biosimilar maker spun out of Merck in 2021.
The all-cash deal came in at $14 per share $OGN and is slated to close early next year, the companies said Sunday evening.
您已阅读19%（360字），剩余81%（1548字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。